A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

This trial is testing a new radioactive drug called 177Lu-BL-ARC001 in people with advanced lung cancer, breast cancer, head and neck cancer, or other solid tumors that have already stopped responding to standard treatments. **You may be eligible if...** - You are 18 or older (up to 75 for the early phase) - You have an advanced or metastatic solid tumor that has not responded to standard treatment - Your tumor is measurable on a scan - You are generally in good physical condition (ECOG 0 or 1) - Your heart, kidneys, liver, and blood counts are within acceptable ranges - You are willing to use contraception during and for 6 months after treatment **You may NOT be eligible if...** - You received chemotherapy or immunotherapy within the past 4–5 weeks - You have a serious heart condition or irregular heartbeat - You have active autoimmune disease - You have another cancer diagnosed in the past 5 years - You have active HIV, hepatitis B, hepatitis C, or tuberculosis - You are pregnant or breastfeeding - You have had an organ or stem cell transplant Talk to your doctor to see if this trial is right for you.